Ipca Labs gets 3 USFDA observations for Piparia facility

Published On 2023-04-27 05:45 GMT | Update On 2023-04-27 05:45 GMT

Mumbai: Ipca Laboratories has recently announced that the US Food and Drug Administration (USFDA) has issued a Form 483 with 3 observations at the conclusion of the inspection at the company's Piparia facility.

The inspection was held from 18 April, 2023 to 26 April, 2023

"This is to inform you that the US FDA conducted the inspection of the Company's formulations manufacturing unit situated at Piparia (Silvassa) from 18th April, 2023 to 26th April, 2023," the company informed in a BSE filing.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"The Company will submit its comprehensive response on these observations to the US FDA within the stipulated time and shall work closely with the agency to resolve these issues at the earliest,"

Ipca further informed.

"The Company takes the quality and compliance issues with utmost importance and remains committed to maintain the highest standards of quality and compliance across all its facilities," Ipca added.

Read also: Ipca Labs to buy 33 percent stake in Unichem Labs for 1,034 crore

Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Ipca Labs gets 3 USFDA observations for Piparia facility

Similar News